Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.
Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.
Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.
Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.
Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.
Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's chair, president and chief executive officer, José (Joe) E. Almeida, will deliver a presentation on Monday, January 13, 2025, at 10:30 a.m. Pacific Time. Interested parties can access the live webcast through www.baxter.com, with replay availability extending until July 12, 2025.
Baxter International (NYSE:BAX) announced five new injectable pharmaceutical product launches in the U.S., bringing their total launches to 10 in 2024. The new products include: Micafungin for Candida infections, Cyclophosphamide Injection for malignant diseases, Pantoprazole Sodium for GERD treatment, Cefazolin in a new 3g/150mL strength for various infections, and Levetiracetam for seizure treatment.
These ready-to-use formats utilize Baxter's proprietary container technology and are designed to improve operational efficiencies, simplify medication preparation, and enhance patient safety by reducing contamination risks and potential compounding errors.
Baxter International (NYSE:BAX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Thursday, December 5, 2024, at 9:10 a.m. Eastern Time. The presentation will be accessible via live webcast on www.baxter.com and will remain available for replay until Tuesday, June 3, 2025.
Baxter International (NYSE:BAX) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Wednesday, November 20, 2024, at 11:00 a.m. GMT. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 19, 2025.
Baxter International (NYSE:BAX) has announced its participation in the Stifel 2024 Healthcare Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Monday, November 18, 2024, at 8:35 a.m. Eastern Time. The presentation will be available via live webcast on www.baxter.com and can be accessed for replay through May 17, 2025.
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.17 per share of common stock, payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share. This new quarterly dividend rate is set in anticipation of the Kidney Care business segment divestiture to Carlyle, expected to close in late 2024 or early 2025. The dividend targets a payout ratio of approximately 25% of adjusted net income, aligning with peer companies. Baxter maintains its 93-year history of consistent dividend payments while balancing business reinvestment with shareholder returns.
Baxter (BAX) reported Q3 2024 total sales of $3.85 billion, with continuing operations sales of $2.70 billion increasing 4% on both reported and constant currency basis. The company achieved total U.S. GAAP diluted EPS of $0.27 and adjusted EPS of $0.80, exceeding previous guidance. Hurricane Helene significantly impacted the North Cove facility, though production has restarted on the highest-throughput IV solutions line. The company announced the pending sale of its Kidney Care business to Carlyle for $3.80 billion, expected to close in late 2024 or early 2025. Due to hurricane impact, Baxter adjusted its full-year 2024 outlook, expecting total company sales growth of 1-2% and adjusted EPS of $2.90-$2.94.
Baxter International (NYSE:BAX) announced its participation in the upcoming UBS Global Healthcare Conference. Chief Financial Officer Joel Grade will deliver a presentation on Wednesday, November 13, 2024, at 1:15 p.m. Pacific Time. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 12, 2025.
Baxter International Inc. (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. Interested participants can pre-register for the call through a provided link to receive call information. The conference call will also be webcast and accessible via Baxter's website at www.baxter.com. Baxter has noted that the call will be recorded and is copyrighted material, prohibiting unauthorized recording or rebroadcasting without the company's permission.
Baxter International Inc. (NYSE:BAX) has provided an update on the impact of Hurricane Helene on its North Cove facility in Marion, N.C. The facility is currently closed for production due to flooding, and the company is working closely with various government agencies to assess the damage and resume operations. Key points:
1. Baxter is implementing measures to minimize supply disruptions, including managing inventory and using a protective allocation process.
2. The company will leverage its global manufacturing network to mitigate potential supply impacts.
3. The Baxter International Foundation has committed $1.5 million in donations for recovery efforts and is matching employee donations 2:1.
4. Baxter anticipates a negative impact on its financial results due to the disruption and plans to provide an update in its third quarter earnings announcement.
FAQ
What is the current stock price of Baxter International (BAX)?
What is the market cap of Baxter International (BAX)?
What does Baxter International Inc. specialize in?
What was the impact of Baxter's acquisition of Hillrom?
What products does Baxter offer for kidney failure patients?
What are some of Baxter's injectable therapies?
What surgical products does Baxter provide?
What is Baxter's plan for its renal care segment?
How does Baxter contribute to global healthcare access?
How does Baxter ensure continuous innovation?
What are some of the digital solutions offered by Baxter?
What is Baxter's commitment to patient care?
